Beijing, China, 16 October 2021 - Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd. (Endovastec™) recently completed the final procedure of the pre-market multicenter clinical trial for the Vflower® Venous Stent System in Beijing, marking the completion of patient enrollment in the trial. The clinical trial for the Vflower® Venous Stent System is a prospective, multi-center, single-arm, nationwide clinical study led by Peking Union Medical College Hospital, in conjunction with The Affiliated Hospital of Qingdao University, and 12 medical centers as co-participators in China. It took just 10 months from the first implantation to the enrollment completion.
The Vflower® Venous Stent System is the first venous product developed by Shanghai Bluevastec MedTech Co., Ltd. (BluevastecTM), a subsidiary of EndovastecTM. Bluevastec™ leveraged the long-established technological foundation of Endovastec™ in vascular stents and delivery devices, coupled with in-depth research on venous morphological characteristics and hemodynamics for the design of this product. Vflower® features a braided structure that provides sufficient support to iliac vein compression and meets the flexibility requirement of distal vein. In addition, the unique design of its delivery system ensures a stable and precise release.
Existing follow-up results show that the Vflower® Venous Stent System has a 100% success rate in terms of device, technical and procedural success. This indicates that the System is able to precisely locate and effectively support the lesion site during a procedure to ensure unobstructed blood flow, as well as the stent's conformity to the physiology of the iliac vein. The completion of this clinical implantation of the Vflower® Venous Stent System fills a gap in the market of domestic venous stents, providing much needed assistance to patients.
Dr. Zhenyu Yuan, Vice President of Endovastec™ and General Manager of Bluevastec™, stated, "Bluevastec™ will continue to focus on developing more venous products and strengthen its product portfolio in this space through in-depth basic research and rich clinical research data to offer more cost-effective solutions for more patients with venous diseases. "
About Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), which is a subsidiary of MicroPort Scientific Corporation, was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New "Little Giant" Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.
MicroPort Scientific Corporation published this content on 17 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2021 02:30:01 UTC.